Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Clinical Infectious Diseases2007Vol. 45(7), pp. 883–893
Citations Over TimeTop 1% of 2007 papers
Peter G. Pappas, C. M. F. Rotstein, Robert F. Betts, Márcio Nucci, Deepak Talwar, Jan J. De Waele, José A. Vázquez, B Dupont, David L. Horn, Luis Ostrosky‐Zeichner, Annette C. Reboli, Byungse Suh, Raghunadharao Digumarti, Chunzhang Wu, Laura Kovanda, L Arnold, Donald N. Buell
Abstract
Dosages of micafungin 100 mg daily and 150 mg daily were noninferior to a standard dosage of caspofungin for the treatment of candidemia and other forms of invasive candidiasis.
Related Papers
- → Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature(2011)145 cited
- → Echinocandin antifungals: review and update(2006)83 cited
- → Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species(2020)16 cited
- → Medical Claims and Current Applications of the Potent Echinocandin Antifungals(2009)2 cited
- The role of caspofungin and the echinocandins in the antifungal armamentarium.(2002)